IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing
proteins, i.e. free from proteins other than the active toxin. Injected into the muscle,
incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used
for treatment of various neurological conditions. This study will investigate the efficacy
and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the
upper limb.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA